Oneness Biotech Co Ltd

Oneness Biotech Co., Ltd., headquartered in Taipei City, Taiwan, functions as a biopharmaceutical enterprise primarily dedicated to the discovery and advancement of novel therapeutic agents, in addition to selling pharmaceutical and health-related merchandise. The company's operations are divided into its New Drug Research and Development segment and its Agricultural Products Cultivation segment. Its advanced therapeutic candidate, ON101, is currently undergoing Phase III clinical trials for the treatment of chronic diabetic foot ulcers. Additionally, OB318, an experimental anti-cancer drug, is progressing through Phase I clinical evaluation. The company's development pipeline further includes FB704A, which has successfully concluded its Phase I clinical trial for addressing rheumatoid arthritis and systemic sclerosis. Furthermore, FB825 is currently in Phase II clinical trials, targeting conditions like atopic dermatitis, various allergic diseases, and asthma. In its earlier stages, FB918, a human monoclonal antibody aimed at allergic asthma, is undergoing pre-clinical development. Beyond its pharmaceutical endeavors, Oneness Biotech also oversees agricultural cultivation and trading activities, encompassing the distribution of farm produce. The company was established and began operations in 2008.